Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
2
pubmed:dateCreated
2003-4-22
pubmed:abstractText
In the present study, we examined the effects of a newly developed bisphosphonate, minodronate (YM529), on osteolytic bone metastasis caused by lung cancer. Human small-cell lung cancer (SBC-5) cells, injected intravenously into natural killer cell-depleted SCID mice, produced radiologically detectable bone metastasis by day 18 and macroscopically visible visceral metastases (lung, liver, kidney, systemic lymph node) by day 35. Prophylactic treatment with YM529 on day 1 significantly inhibited the formation of osteolytic bone metastasis evaluated on X-ray photographs in a dose-dependent manner. In addition, treatment with YM529 after establishment of bone metastasis (on day 21) also inhibited bone metastasis, although the treatment was more effective when started earlier. Single administration was as effective as repeated treatment, suggesting a sustained inhibitory effect of YM529 on bone metastasis. YM529 reduced the number of osteoclasts in the bone metastatic lesions in vivo, but had no effect on the proliferation or cytokine production of SBC-5 cells in vitro. These results suggest that YM529 is a potent inhibitor of bone metastasis of human lung cancer, probably by suppressing osteoclastic bone resorption. In contrast, treatment with YM529 had no effect on visceral metastasis, even if started on day 1, and did not prolong the survival of the mice. Therefore, development of a combined modality is necessary for prolonging the survival of small-cell lung cancer patients with multiple-organ metastasis.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Antineoplastic Agents, http://linkedlifedata.com/resource/pubmed/chemical/Cytokines, http://linkedlifedata.com/resource/pubmed/chemical/Diphosphonates, http://linkedlifedata.com/resource/pubmed/chemical/Endothelial Growth Factors, http://linkedlifedata.com/resource/pubmed/chemical/Imidazoles, http://linkedlifedata.com/resource/pubmed/chemical/Intercellular Signaling Peptides..., http://linkedlifedata.com/resource/pubmed/chemical/Lymphokines, http://linkedlifedata.com/resource/pubmed/chemical/PTHLH protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Parathyroid Hormone-Related Protein, http://linkedlifedata.com/resource/pubmed/chemical/Peptide Hormones, http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factor A, http://linkedlifedata.com/resource/pubmed/chemical/Vascular Endothelial Growth Factors, http://linkedlifedata.com/resource/pubmed/chemical/YM 529
pubmed:status
MEDLINE
pubmed:issn
0262-0898
pubmed:author
pubmed:issnType
Print
pubmed:volume
20
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
153-9
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:12705636-Animals, pubmed-meshheading:12705636-Antineoplastic Agents, pubmed-meshheading:12705636-Bone Neoplasms, pubmed-meshheading:12705636-Bone Resorption, pubmed-meshheading:12705636-Carcinoma, Small Cell, pubmed-meshheading:12705636-Cell Division, pubmed-meshheading:12705636-Cytokines, pubmed-meshheading:12705636-Diphosphonates, pubmed-meshheading:12705636-Disease Models, Animal, pubmed-meshheading:12705636-Dose-Response Relationship, Drug, pubmed-meshheading:12705636-Endothelial Growth Factors, pubmed-meshheading:12705636-Humans, pubmed-meshheading:12705636-Imidazoles, pubmed-meshheading:12705636-Immunoenzyme Techniques, pubmed-meshheading:12705636-Intercellular Signaling Peptides and Proteins, pubmed-meshheading:12705636-Kidney Neoplasms, pubmed-meshheading:12705636-Killer Cells, Natural, pubmed-meshheading:12705636-Liver Neoplasms, pubmed-meshheading:12705636-Lung Neoplasms, pubmed-meshheading:12705636-Lymphatic Metastasis, pubmed-meshheading:12705636-Lymphocyte Depletion, pubmed-meshheading:12705636-Lymphokines, pubmed-meshheading:12705636-Male, pubmed-meshheading:12705636-Mice, pubmed-meshheading:12705636-Mice, SCID, pubmed-meshheading:12705636-Osteolysis, pubmed-meshheading:12705636-Parathyroid Hormone-Related Protein, pubmed-meshheading:12705636-Peptide Hormones, pubmed-meshheading:12705636-Severe Combined Immunodeficiency, pubmed-meshheading:12705636-Tumor Cells, Cultured, pubmed-meshheading:12705636-Vascular Endothelial Growth Factor A, pubmed-meshheading:12705636-Vascular Endothelial Growth Factors
pubmed:year
2003
pubmed:articleTitle
A novel bisphosphonate minodronate (YM529) specifically inhibits osteolytic bone metastasis produced by human small-cell lung cancer cells in NK-cell depleted SCID mice.
pubmed:affiliation
Department of Internal Medicine and Molecular Therapeutics, University of Tokushima School of Medicine, Tokushima, Japan.
pubmed:publicationType
Journal Article, Comparative Study